Dhule-Nandurbar is a 37.8MW onshore wind power project. It is planned in Maharashtra, India. According to GlobalData, who tracks and profiles over 170,000 power plants worldwide, the project is currently at the partially active stage. It will be developed in multiple phases. Post completion of the construction, the project is expected to get commissioned in March 2011. Buy the profile here.
Smarter leaders trust GlobalData
Description
The project is being developed and currently owned by Serum Institute of India. The company has a stake of 100%.
The project is expected to supply enough clean energy to power 8,000 households.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase IA), will be using Tubular Steel towers.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase IB), will be using Tubular Steel towers.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase IC), will be using Tubular Steel towers.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase ID), will be using Tubular Steel towers.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase IE), will be using Tubular Steel towers.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase IF), will be using Tubular Steel towers.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase IG), will be using Tubular Steel towers.
The turbines that are getting installed on the Dhule-Nandurbar (Dhule-Nandurbar Phase II), will be using Tubular Steel towers.
Development status
Post completion of the construction, the project is expected to get commissioned in March 2011.
Contractors involved
Suzlon Energy will be the turbine supplier for the wind power project. The project consists of 18 units of S88-2.1 MW turbines, each with 2.1MW nameplate capacity.
Suzlon Energy is expected to perform operations and maintenance for the wind power project. The O&M tenure will likely be commencing from the year 2011.
See Also:
For more details on Dhule-Nandurbar, buy the profile here.
About Serum Institute of India
Serum Institute of India Pvt Ltd (Serum Institute), a subsidiary of Cyrus Poonawalla Group, is a biotechnology company that manufactures and supplies vaccines and immuno-biologicals to treat polio, diphtheria, tetanus, pertussis, r-hepatitis B, measles, mumps and rubella. The company's product portfolio includes bacterial, viral, covid, influenza, polysaccharide conjugate and combination vaccines; recombinant and pharma products; and anti-sera vaccines. It markets the Oxford–AstraZeneca COVID-19 vaccine under the brand name Covishield in India. It is investigating DTaP, an acellular vaccine against pertussis; pentavalent meningococcal conjugate vaccine to prevent epidemic group A meningococcal disease; ErepoXen, to maintain red blood cell production and prevent anemia caused by chronic kidney failure; and HPV vaccine against cervical cancer. Serum Institute is headquartered in Pune, Maharashtra, India
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying research used to produce this article.
This information is drawn from GlobalData’s Power Intelligence Center, which provides detailed profiles of over 170,000 active, planned and under construction power plants worldwide from announcement through to operation across all technologies and countries worldwide.
